Skip to content

King Pharmaceuticals KG International — Year 4

Other product segments

Commercial Auto Liability
18.2%
General Liability
15.9%
European Hospital Liability
13.7%
All other lines
4.7%

Similar metrics at other companies

CNA Financial logo
CNAInternational — Year 10
1.3%
CNA Financial logo
CNAInternational — Year 8
2.6%
CNA Financial logo
CNAInternational — Year 7
5.6%
CNA Financial logo
CNAInternational — Year 9
2.8%
CNA Financial logo
CNAInternational — Year 4
6.8%
Hagerty logo
HGTYInternational — Revenue
$13.08M+87.0%

Other financials

Income statement

See full
Revenue$10.2M+1,112%
Net income-$7.4M-1,786%
EPS (diluted)-$0.96-586%

Balance sheet

See full
Cash & equivalents$62.2M+1,724%
Total debt$176.7M
Total equity$121.4M+2,773%
Total assets$964.2M

Cash flow

See full
Operating cash flow-$15.1M-1,628%

Valuation

See full
Market cap$70.42M-67.6%
Enterprise value$184.93M-50.0%
P/E1.2×
P/S1.6×-24.3×

Profitability

See full
Net margin131.5%

Returns & leverage

See full
Return on equity90.8%
Debt / equity1.5×

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ShortdurationInsuranceContractsHistoricalClaimsDurationYearFour.

The official record: King Pharmaceuticals’s 10-K, filed March 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's international — year 4.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is King Pharmaceuticals's international — year 4?
King Pharmaceuticals (KG) reported international — year 4 of -0.3% in Q4 2025.
What does international — year 4 mean?
Represents the financial performance and operational results of the International insurance product line during the fourth year of the reporting cycle. This metric captures revenue, underwriting outcomes, and risk exposure specific to international markets. It serves as a baseline for evaluating long-term growth trends within the global segment.